Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Mainz Biomed B.V. ( (MYNZ) ) has provided an announcement.
Mainz Biomed announced the pricing of an $8 million follow-on offering, with each unit sold consisting of shares and warrants, priced under Nasdaq rules. This offering supports the company’s ongoing operations and position in the molecular genetics diagnostics industry, as it continues its pivotal FDA clinical study for US market entry.
More about Mainz Biomed B.V.
Mainz Biomed NV is a molecular genetics diagnostic company that develops market-ready solutions for the early detection of life-threatening conditions. Its flagship product, ColoAlert®, is a non-invasive diagnostic test for colorectal cancer marketed across Europe, and the company is seeking FDA approval in the US. Mainz Biomed’s portfolio also includes PancAlert, a diagnostic test for pancreatic cancer.
YTD Price Performance: -87.93%
Average Trading Volume: 101,896
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $11.21M
Learn more about MYNZ stock on TipRanks’ Stock Analysis page.
